Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: GlobeNewswire
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago. Presentation Details Title: Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of ?8 Transmembrane AMPA Receptor Regulatory Protein: Impact on RNS Long Episodes and Clinical SeizuresPresenter: William W. Motley, M.D., RAP-219 Program Leader at Rapport TherapeuticsSession Type: Scientific Platform SessionDate & Time: April 21, 2026
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy [Yahoo! Finance]Yahoo! Finance
- Rapport Therapeutics (RAPP) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China [Yahoo! Finance]Yahoo! Finance
- Rapport Therapeutics (RAPP) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RAPP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hMarketBeat
- Rapport Therapeutics (RAPP) had its price target raised by Wells Fargo & Company from $43.00 to $46.00. They now have an "overweight" rating on the stock.MarketBeat
RAPP
Earnings
- 3/10/26 - Miss
RAPP
Sec Filings
- 3/31/26 - Form 4
- 3/30/26 - Form 144
- 3/26/26 - Form 4
- RAPP's page on the SEC website